Fellowship

Fellowship with Forbion 

Are you interested in life sciences venture capital investments? Have you recently completed your MD or PhD in biomedical sciences, and considering a career in the life sciences investment industry? Can you see yourself putting your scientific training to use to evaluate new ideas, analyse companies and identify unique investment opportunities? Then consider applying for a fellowship with Forbion. 

Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, The Netherlands, Munich, Germany and Boston, USA. Forbion invests in innovative biotech companies, managing €5  billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Our portfolio is focused on novel therapeutics across different treatment modalities and disease areas, including small molecules, biologics and genetic medicines for oncology, CNS, autoimmune, cardiometabolic and rare diseases. 

We offer a unique opportunity for personal and professional development in a dynamic, ambitious and professional work environment. You will gain exposure to a wide range of company due diligence activities, and interact with other investors, academic and industry experts in the life science industry.    

This role will allow you to develop your analytical skills as you assess life sciences companies to identify value through scientific, clinical, regulatory, commercial and financial perspectives. You will learn and work alongside a diverse international team of investors with extensive experience in the life sciences. 

The primary role of the fellow will be to support daily deal flow management and initial evaluation of new investment opportunities and landscaping projects. Other activities will include support of investment due diligence and special projects. This activity is expected to provide exposure to several biotech companies spanning a range of therapeutic areas and stages of development. 

The fellowship is for 6-9 months on a full-time basis working at the Forbion head office in Amsterdam, The Netherlands. Physical presence is required.  

Professional and Personal Qualifications 

We are looking for a candidate that has: 

• Recently graduated with an MD or PhD/post-doc in biomedical sciences, medicine, pharmacology or similar
• Strong academic results – GPA in top of the class from highly ranked university
• Demonstrated interest in life sciences innovation
• Previous experience in investment or strategy consulting is a plus
• Fluent communication in English, both verbal and written
• International experience is appreciated
• Right to live and work in the EU 

As a person, you are: 

• Independent, self-motivated with a strong work ethic 
• Ambitious, proactive, show attention to detail and possess a structured approach to problem-solving 
• Intellectually curious, disciplined, resourceful and resilient 
• Able to work as a team player with a high sense of responsibility 

 Studying for an MBA or MSc in finance? Recent MBA/MSc graduates, or current students with an option to do an internship, are also encouraged to apply, provided you also meet the other criteria, notably a biomedical degree, and ability to commit to 6 months full time. 

Working at Forbion 

Forbion has a respectful and collaborative work culture where your opinion is valued. We are committed to diversity, equity, and inclusion. We welcome applicants regardless of background, orientation, and nationality. You will enjoy the opportunity to be part of a dedicated, international dynamic team with diverse backgrounds.  

Application and Information

Please note that applications that do not meet the requirements will not be considered. Only applicants that fulfil all the stipulated criteria will be contacted. 

To apply, please send your CV and motivation letter using the link below.

Application deadline is Friday 2nd of May 2025.

First round interviews and case studies will take place in May, final interviews in June.

Starting date expected to be August or September 2025.